Key result
Early diagnosis and personalized treatment enhance prognosis for pulmonary hypertension, which affects ~1% globally.
This review highlights the definition, pathophysiology, and importance of early diagnosis and personalized treatment in improving outcomes for patients with pulmonary hypertension.
Early PH diagnosis and risk stratification may improve prognosis; leaves open optimal personalized strategies in Level 4 data.
Pulmonary hypertension (PH) is a heterogeneous condition defined by an increase in mean pulmonary arterial pressure over 20 mm Hg diagnosed through right heart catheterization. Its global prevalence is around 0.6% to 1%. The prognosis used to be poor but nowadays early diagnosis, risk stratification, and a personalized treatment can significantly enhance the prognosis and quality of life of these patients. PH pathophysiology comprises genetic and environmental factors, such as endothelial dysfunction, smooth muscle cell proliferation, inflammation, thrombosis, and right ventricular remodeling. Especially in pulmonary arterial hypertension, treatment options have been radically altered.
No takes yet. Share an insight, caveat, or question.
Nardi et al. (2026) conducted a review in Pulmonary hypertension. Pulmonary hypertension has a global prevalence of 0.6% to 1%, and its prognosis can be significantly enhanced through early diagnosis, risk stratification, and personalized treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: